SpaceX reported strong Q3 results with revenue up 161% year-over-year and adjusted EBITDA rising 306%. The company's rapidly expanding compute segment is now the main growth driver, with plans to reach up to 13 gigawatts of capacity by the end of 2027. This growth is supported by strong external demand and flexible compute allocation, which could help SpaceX fund its own AI development while monetizing capacity at attractive prices. Despite these positives, the stock is rated Hold due to a high 67x price-to-earnings ratio projected for 2027, potential normalization of compute pricing, and ongoing IPO lockup expirations.
SpaceX's recent growth story is presented here with Pluang's Technology sector data for context. As of Oct 24, 2026 03:11 WIB, 79 of 150 Technology stocks rose while 70 fell. Notable movers include BlackBerry Limited at USD 8.50 down 9.67%, Credo Technology Group Holding Ltd at USD 147.80 down 9.20%, and Fastly Inc at USD 24.50 up 9.13%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
